{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.07","statisticalComment":"adjusting for the stratification factor (Hepatocellular carcinoma versus liver metastases)","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"groups":[{"description":"Patients receive a radiation therapy with the use of 8 Gy in one fraction to the whole (or near-whole) liver together with the best supportive care.","id":"OG000","title":"Radiotherapy Combined With Best Supportive Care"},{"description":"Patients receive only the best supportive care.","id":"OG001","title":"Best Supportive Care Alone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who completed both baseline and day 30 pain/discomfort assessments and reported taking opioid medications in the 24 hours prior to their both baseline and day 30 assessments","reportingStatus":"POSTED","timeFrame":"30 days","title":"Proportion of Patients Achieving Improvement of Liver Cancer Pain/Discomfort by ≥ 2 Points in Pain \"Intensity at Worst \" AND With no Increase in Opioid Use (Employing Daily Morphine Equivalence Scale) on BPI From Baseline to 30 Days.","type":"SECONDARY","unitOfMeasure":"Participants"}